Cancer

The main purpose of this study is to compare the effects of one of two different dose levels of an investigational drug called GC4419 when given with the standard radiation therapy and chemotherapy for the treatment of head and neck cancers. This study drug is not yet approved by the FDA. The study will be looking at the effect that the drug GC4419 will have on mucositis, which is a side effect of the chemotherapy and radiation therapy for the treatment of head and neck cancers.

The purpose of this study is to determine the maximum tolerated dose of RX-0201, up to a target dose of 250 mg/m^2/day, when given in combination with everolimus (Stage 1), and to assess the safety and efficacy of RX-0201 plus everolimus, in subjects with metastatic renal cell cancer (Stage 2).

The purpose of this study screening step is to perform tests on genes and proteins produced by genes in your tumor sample for certain features that investigational targeted agents used in this study are specifically designed to work against. Then the purpose is to assign you to a treatment sub-study that is chosen based on the results (genes and proteins called “biomarkers”) of this genetic testing on your tumor sample. These study related “research tests” will be done in a special lab.

Primary Aims
1.1.1 To compare EFS in patients with newly diagnosed T-ALL and T-LLy who are randomized to a modified ABFM backbone versus bortezomib plus the modified ABFM backbone.
1.2 Secondary Aims
1.2.1 To determine the safety and feasibility of modifying standard therapy for T-ALL and T-LLy based on the results of UKALL 2003, which includes a dexamethasone-based Induction, additional doses of pegaspargase (PEG-ASP) during Induction and Delayed Intensification (DI), and dexamethasone pulses during Maintenance therapy

The purpose of this study is to compare the effects, good and/or bad, of temozolomide versus temozolomide plus capecitabine on the subjects and the subjects’advanced pancreatic neuroendocrine tumor cancer to find out which is better. In this study, subjects will get either temozolomide alone or temozolomide and capecitabine. Temozolomide and capecitabine are chemotherapy drugs, which have benefited some patients with pancreatic neuroendocrine tumors yet they have never been compared; both arms are considered investigational.